About Kardigan
Kardigan is a company based in San Francisco (United States) founded in 2023 by Tassos Gianakakos. Kardigan has raised $554 million across 2 funding rounds from investors including Fidelity Investments, T. Rowe Price and Arch Venture Partners. Kardigan has completed 1 acquisition, including Prolaio. Kardigan offers products and services including Personalized Medicines, R&D Platform, and Cardiac Intelligence Platform. Kardigan operates in a competitive market with competitors including Suanfarma, Enzene Biosciences, Hybio Pharmaceutical, Nephron Pharmaceuticals and Quotient Sciences, among others.
- Headquarter San Francisco, United States
- Founders Tassos Gianakakos
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$554 M (USD)
in 2 rounds
-
Latest Funding Round
$254 M (USD), Series B
Oct 14, 2025
-
Investors
Fidelity Investments
& 4 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kardigan
Kardigan offers a comprehensive portfolio of products and services, including Personalized Medicines, R&D Platform, and Cardiac Intelligence Platform.
Targets specific cardiovascular disease drivers for effective treatments.
Uses AI to optimize clinical trials and drug discovery processes.
Analyzes real-world data for safer and more efficient drug development.
People of Kardigan
Unlock access to complete
Funding Insights of Kardigan
Kardigan has successfully raised a total of $554M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $254 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Kardigan
Kardigan has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, T. Rowe Price and Arch Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
Investment services are offered to ambitious builders worldwide.
|
Locked | Locked | Locked |
Investor details for Kardigan
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kardigan
Kardigan has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Prolaio.
Investment portfolio details for Kardigan
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Company offers prescriptive analytics for pharmaceutical Industry
|
Locked | Locked | 2021 | Locked |
Complete acquisition details for Kardigan
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Kardigan
Detailed financials for Kardigan
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kardigan Comparisons
Peer comparison for Kardigan
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kardigan
Kardigan operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Suanfarma, Enzene Biosciences, Hybio Pharmaceutical, Nephron Pharmaceuticals and Quotient Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Generics, nutraceuticals, and APIs are developed by Suanfarma.
|
|
| Locked | Locked | Locked |
Company specializing in development of Biosimilars
|
|
| Locked | Locked | Locked |
Polypeptide drugs and APIs are developed and manufactured.
|
|
| Locked | Locked | Locked |
Sterile pharmaceutical products are manufactured and contract services are provided.
|
|
| Locked | Locked | Locked |
APIs and finished dosage forms are developed and manufactured.
|
Detailed competitors of Kardigan
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kardigan
Complete news archive for Kardigan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kardigan
Kardigan was founded in 2023 and raised its 1st funding round 2 years after it was founded.
Kardigan is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Tassos Gianakakos is the current CEO of Kardigan. They have also founded this company.
Kardigan is a funded company, having raised a total of $554M across 2 funding rounds to date.
Kardigan was founded in 2023 in San Francisco, United States, as a biotechnology company. Precision medicines for cardiovascular diseases are developed, with operations centered on a late-stage portfolio. Cardiovascular drug development is modernized through personalized approaches, targeting patient-specific treatments in the biotech sector.
Kardigan's top competitors include Nephron Pharmaceuticals, Suanfarma and Enzene Biosciences.
Kardigan offers Personalized Medicines, R&D Platform, and Cardiac Intelligence Platform.
Kardigan has made 1 acquisition, including Prolaio.
Kardigan has 5 investors. Key investors include Fidelity Investments, T. Rowe Price, Arch Venture Partners, Perceptive Advisors, and Sequoia Heritage.